Caris Molecular Intelligence™ makes it possible to measure a wide range of cancer biomarkers (proteins, genes and other molecules that affect the growth, reproduction and response of cancer cells to treatment) and interpret the results to identify the types of treatment most likely to benefit the patient. It may also help eliminate treatments unlikely to benefit the patient.
Results contained in the MI Profile Report enable oncologists to determine better the types of treatment appropriate for a particular patient on the basis of their individual cancers, and not areas of the tumour.
Using a range of advanced technologies, and evaluating relevant biological components of the patient’s cancer, Caris Molecular Intelligence relates the changes of biological characteristics of the tumour of each patient with the most reliable data, as reflected in clinical literature on oncology.
Your request will be processed by AMAXA on obtaining the following documents:
To arrange a test or request more information, please send your request via email to firstname.lastname@example.org. AMAXA is the authorised representative for providing the Caris Molecular Intelligence service. It sends samples to the Caris laboratory, oversees the preparation and receipt of the report (with a list of medicines in the most and the least suitable for the treatment of the patient) and transmits the report to the attending physician.
Caris Molecular Intelligence helps to create a treatment plan if there is any doubt as to the treatment of patients with inoperable primary or metastatic tumours.
Caris Molecular Intelligence allows physicians to:
Despite being developed to study solid tumours, including cancers of unknown primary sites, the Caris Molecular Intelligence study is particularly important in determining the treatment method of:
Multi-platform analysis of biomarkers of various kinds of tumours allows physicians to determine the course of treatment of solid tumours, including mutational analysis being made by the next-generation sequencing methods for a deeper analysis of biomarkers.